Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. (Nasdaq: ZTEK, TSX-V: ZEN) is an intellectual property development and commercialization company focusing on next-generation healthcare solutions for prevention, detection, and treatment. Zentek is at the forefront of commercializing ZENGuard, a groundbreaking coating with 99% antimicrobial effectiveness, including activity against COVID-19. This technology has applications in a variety of fields, including surgical masks and HVAC systems.
The company operates a state-of-the-art production facility in Guelph, Ontario, and is ISO 13485:2016 certified. Zentek has developed a synergistic relationship with McMaster University to leverage an exclusive global license for their aptamer-based rapid pathogen detection technology. This partnership has led to promising results, including the C19HBA aptamer, which has shown therapeutic potential against SARS-CoV-2, outperforming leading monoclonal antibodies in preclinical trials.
Through its wholly-owned subsidiary Triera Biosciences Ltd., Zentek continues to advance its aptamer technology. Notably, their C19HBA aptamer has demonstrated robust preclinical efficacy in both prophylactic and therapeutic settings against various SARS-CoV-2 variants, including Omicron XBB 1.5. The company is now moving towards Phase 1 clinical trials and exploring further applications for their platform in infectious diseases and oncology.
In addition to healthcare, Zentek has made significant strides in the HVAC industry. The company's ZenGUARD™ Enhanced Air Filters aim to improve air quality without increasing energy consumption or emissions. Zentek's commitment to innovation is further evidenced by a series of partnerships and distribution agreements, including collaborations with Medwell Solutions LLC and DCL Supply Ltd. These partnerships aim to expand the market reach of Zentek's antimicrobial technologies.
Recent Achievements:
- Significant progress in preclinical trials for C19HBA aptamer as a therapeutic for SARS-CoV-2.
- A promising safety and toxicity profile for the C19HBA aptamer in preclinical tests.
- Exclusive distribution agreements for ZenGUARD™ Enhanced Surgical Masks in the U.S. with Medwell Solutions LLC and DCL Supply Ltd.
- Launch preparations for ZenGUARD™ Enhanced Air Filters in the HVAC market.
- Second patent for their GO-Ag+ nanocomposite as an antimicrobial agent, expanding its potential applications to both human and veterinary medicine.
Zentek continues to focus on commercializing its proprietary technologies, aiming to provide significant health benefits while also addressing environmental concerns. By offering innovative, safer, and greener products, Zentek seeks to give its commercial partners a competitive edge in their respective markets.
Zentek Ltd. (Nasdaq:ZTEK, TSX-V:ZEN) has filed a provisional patent for its ZenGUARD™ technology as an anti-inflammatory agent for various dermatological conditions. CEO Greg Fenton emphasized their commitment to patenting and commercialization of ZenGUARD™, which is already authorized by Health Canada as an antimicrobial for surgical masks and PPE. Current research aims to explore its potential for treating conditions like acne, psoriasis, and eczema. The company is collaborating with Vimta Labs for pre-clinical data needed for FDA drug submission.
Zentek Ltd. (NASDAQ:ZTEK) announced the appointment of Ilse Treurnicht to its Board of Directors. Treurnicht, who holds a DPhil in chemistry from Oxford, is the Managing Partner of TwinRiver Capital and has significant Board-level experience, including her role as CEO of the MaRS Discovery District. She has been awarded 250,000 options at $2.44, with a vesting schedule over five years. Zentek focuses on innovative healthcare solutions, including its ZenGUARD antimicrobial coating and exclusive rights to a rapid pathogen detection technology.
Zentek Ltd. (NASDAQ:ZTEK) has initiated the Canadian national phase for its ZenGUARD™ patent application as of March 28, 2022. This technology aims to enhance personal protective equipment and HVAC systems. A second patent application focused on ZenGUARD™ as an antimicrobial treatment is set to publish on June 20, 2022, with 58 of 64 claims deemed patentable. Additionally, Zentek filed for a manufacturing process patent on April 12, 2022, aimed at reducing costs. CEO Greg Fenton emphasized the company's commitment to protecting its innovations to ensure long-term shareholder value.
Zentek Ltd. (NASDAQ: ZTEK) announced the grand opening of its industrial-scale ZenGUARD antimicrobial production facility in Guelph, Ontario, scheduled for June 17, 2022. This facility is among the largest in the world for nanomaterials-based manufacturing and supports Zentek's trajectory from laboratory to commercial success. ZenGUARD is a patent-pending coating with 99% antimicrobial effectiveness, targeting the growing demand for transmission prevention products. The company is also exploring applications in the HVAC market to generate additional revenue.
Zentek Ltd. (NASDAQ:ZTEK; TSX-V:ZEN) announced that McMaster University received two NSERC Grants for its aptamer-based rapid detection technology. The Alliance Missions Grant totals $1,000,000, while the Idea to Innovation Grant amounts to $350,000, with Zentek contributing $140,000. These funds will further enhance the commercialization of the rapid diagnostic platform, particularly in optimizing chip synthesis and developing a universal aptamer for COVID variants. This endorsement underlines the potential of Zentek's technology in the healthcare sector.
Zentek Ltd. (Nasdaq:ZTEK) announces the appointment of Wendy Ford as the new Chief Financial Officer, effective immediately. With over 30 years of experience, she aims to optimize operations and enhance shareholder value. Brian Bosse transitions to Chief Operations Officer, further strengthening leadership during a pivotal growth phase following Zentek's recent Nasdaq listing. Additionally, Moe Deib will join as Director of Global Healthcare Sales on May 24, 2022, focusing on selling ZenGUARD™ technology. ZenGUARD™ exhibits 99% antimicrobial activity and supports Zentek's healthcare commercialization strategy.
Zentek Ltd. (NASDAQ:ZTEK) has secured an initial order of ZenGUARD™ coated masks from Mark's, a leading Canadian retailer. This partnership will enhance the product's visibility in over 380 stores across Canada and online, offering a high-quality, Canadian-made option for safety wear. ZenGUARD™ provides 99% antimicrobial activity, including against COVID-19, positioning Zentek as a key player in innovative healthcare solutions. The collaboration may also open doors for future applications of Zentek's nanotechnologies.
Zentek Ltd. (Nasdaq:ZTEK; TSX-V:ZEN) has engaged The Benchmark Company as a strategic financial advisor for potential transactions related to its Albany Graphite Deposit in Northern Ontario. The engagement comes amid growing interest in North American sourced battery-grade graphite. CEO Greg Fenton emphasized the importance of Benchmark's expertise in evaluating commercial opportunities. Zentek owns 100% of the Albany Deposit and continues to focus on developing healthcare solutions, including the antimicrobial coating ZenGUARD.
Zentek Ltd. (NASDAQ:ZTEK) has announced a definitive supply agreement with EkoMed Global Inc. to enhance personal protective equipment (PPE) using Zentek's proprietary ZenGUARD™ coating. This collaboration aims to initially treat surgical masks with the ZenGUARD™ technology, known for its 99% antimicrobial activity. EkoMed's capabilities include the production of over 1.2 billion masks annually, positioning Zentek for greater market access and potential innovations in PPE. CEO Greg Fenton highlighted the strategic importance of this partnership for expanding ZenGUARD™ sales globally.
Zentek Ltd. (NASDAQ: ZTEK), a Canadian intellectual property development firm, has announced the successful completion of Phase 1 testing for its ZenGUARD™-coated HVAC filters. Following this, the company will advance to Phase 2 testing under its Innovation Solutions Canada contract. Phase 1 confirmed the coating's effectiveness in reducing airborne organisms while maintaining airflow. The upcoming Phase 2 aims to further validate the coating's safety and efficacy in a classroom setting. This progression is significant for indoor air quality initiatives and commercialization efforts.
FAQ
What is the current stock price of Zentek (ZTEK)?
What is the market cap of Zentek (ZTEK)?
What is Zentek Ltd. specialized in?
What is ZENGuard?
What recent advancements has Zentek made in healthcare?
Who are Zentek's key partners?
What is Triera Biosciences Ltd.?
What is the latest news about Zentek?
Where is Zentek located?
What industries does Zentek serve?
What technology platforms does Zentek use?
How can I contact Zentek for more information?
